Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPPL1 | O15357 | 2/20 | 0.55 |
| ▸ | MET | P08581 | 6/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.48 |
| ▸ | MAP4K3 | Q8IVH8 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL321751 | 0.99 | INPPL1 (0.54) | INPPL1METALKEGFRERBB2 | |
| SCHEMBL320855 | 0.89 | MAP4K1 (0.56) | METALKCHRNB2CHRNA4IRAK4 | |
| SCHEMBL319690 | 0.88 | MET (0.52) | INPPL1MET | |
| SCHEMBL2321067 | 0.83 | INPPL1 (0.50) | INPPL1METALKEGFRERBB2 | |
| Hydrochloric Acid SCHEMBL2324061 | 0.83 | INPPL1 (0.49) | INPPL1METALKEGFRERBB2 | |
| SCHEMBL319837 | 0.82 | CCNC (0.49) | MET | |
| SCHEMBL10153117 | 0.79 | NTRK1 (0.51) | METIRAK4 | |
| Hydrochloric Acid SCHEMBL320673 | 0.79 | NTRK1 (0.51) | METIRAK4 | |
| SCHEMBL320680 | 0.76 | MET (0.46) | METMAP4K3IRAK4 | |
| SCHEMBL2324841 | 0.76 | MAP4K3 (0.47) | METALKMAP4K3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051307-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051307-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051307-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| EP-2590946-B1 | Bipyridyl derivatives useful for the treatment of kinase-induced diseases | MERCK PATENT GMBH (DE) | 2015-02-18 | — | — | EP | disclosed |
| EP-2590946-B1 | Bipyridyl derivatives useful for the treatment of kinase-induced diseases | MERCK PATENT GMBH (DE) | 2015-02-18 | — | — | EP | disclosed |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8846931-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846931-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846931-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| EP-2590946-A1 | BIPYRIDYL DERIVATIVES USEFUL FOR THE TREATMENT OF KINASE - INDUCED DISEASES | Merck Patent GmbH (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2012003912-A1 | BIPYRIDYL DERIVATIVES USEFUL FOR THE TREATMENT OF KINASE - INDUCED DISEASES | MERCK PATENT GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012003912-A1 | BIPYRIDYL DERIVATIVES USEFUL FOR THE TREATMENT OF KINASE - INDUCED DISEASES | MERCK PATENT GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | TGFBR1, TGFBR2, SMAD2 | INPPL1 297/4885MET 341/4885ALK 955/4885 |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | TGFBR1, TGFBR2, SMAD2 | INPPL1 297/4885MET 341/4885ALK 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.